Cheng Yan

Cheng Yan

Auto-generated profile, based on publicly available information

Cheng Yan

Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Cancer Research
Verified
Journal Article
Open access
GLGuang-Tan Lin
Guang-Tan Lin
CYCheng Yan
Cheng Yan
LLLu-Jie Li
Lu-Jie Li
XQXiao-Wen Qiu
Xiao-Wen Qiu
YZYu-Xuan Zhao
Yu-Xuan Zhao
LCLong-Long Cao
Long-Long Cao
Immune checkpoint blockade (ICB) therapies have achieved significant breakthroughs in cancer treatment over the past decade. However, ICB is largely ineffective in desert-type gastric cancer due to intrinsic tumor heterogeneity and a highly immunosuppressive tumor microenvironment (TME). Transforming tumors from an immunosuppressive state to an immunostimulatory state is a potential approach to enhance ICB response. In this study, we developed a chromosomal instability–subtype gastric cancer mouse model with an immunoactive TME and a stem cell–originated mouse-derived allograft model with an immunosuppressed TME to investigate mechanisms regulating the tumor immunophenotype and uncover therapeutic strategies to remodel the TME. Blocking β-catenin signaling attenuated the immunochemotherapeutic resistance of mouse-derived allograft tumors. The tyrosine kinase inhibitor apatinib reprogrammed the TME by increasing CD8+ T-cell and IGHA+ plasma cell infiltration and decreasing M2 macrophages, but apatinib also induced PD-L1 and CD80 expression in both human and mouse desert–type tumors. Oxaliplatin decreased the apatinib-induced expression of immune checkpoints and enhanced the antitumor efficacy of immunotherapy. A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type gastric cancer. Collectively, these findings identify potential drug targets for immune desert–type gastric cancer driven by β-catenin signaling. Significance: Apatinib combined with oxaliplatin reprograms the tumor immune microenvironment in desert-type gastric cancer, enhancing the efficacy of immune checkpoint blockade and paving the way for optimized combination immunotherapeutic strategies.

2 June 2025
Verified
Other
Open access
PDF file
GLGuang-Tan Lin
Guang-Tan Lin
CYCheng Yan
Cheng Yan
LLLu-Jie Li
Lu-Jie Li
XQXiao-Wen Qiu
Xiao-Wen Qiu
YZYu-Xuan Zhao
Yu-Xuan Zhao
LCLong-Long Cao
Long-Long Cao
A transgenic mouse model and mouse-derived allografts of gastric cancer.

2 June 2025
Verified
Other
Open access
PDF file
GLGuang-Tan Lin
Guang-Tan Lin
CYCheng Yan
Cheng Yan
LLLu-Jie Li
Lu-Jie Li
XQXiao-Wen Qiu
Xiao-Wen Qiu
YZYu-Xuan Zhao
Yu-Xuan Zhao
LCLong-Long Cao
Long-Long Cao
Neoadjuvant regimen of apatinib plus camrelizumab and chemotherapy is effective for patients with desert-type GC.

2 June 2025
Verified
Other
Open access
GLGuang-Tan Lin
Guang-Tan Lin
CYCheng Yan
Cheng Yan
LLLu-Jie Li
Lu-Jie Li
XQXiao-Wen Qiu
Xiao-Wen Qiu
YZYu-Xuan Zhao
Yu-Xuan Zhao
LCLong-Long Cao
Long-Long Cao
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy

2 June 2025
Verified
Other
Open access
GLGuang-Tan Lin
Guang-Tan Lin
CYCheng Yan
Cheng Yan
LLLu-Jie Li
Lu-Jie Li
XQXiao-Wen Qiu
Xiao-Wen Qiu
YZYu-Xuan Zhao
Yu-Xuan Zhao
LCLong-Long Cao
Long-Long Cao
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy